A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Xencor Inc stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 34,894 shares of XNCR stock, worth $594,593. This represents 0.0% of its overall portfolio holdings.

Number of Shares
34,894
Previous 30,774 13.39%
Holding current value
$594,593
Previous $582,000 20.45%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$15.7 - $21.65 $64,684 - $89,198
4,120 Added 13.39%
34,894 $701,000
Q2 2024

Aug 14, 2024

SELL
$18.21 - $24.5 $56,323 - $75,778
-3,093 Reduced 9.13%
30,774 $582,000
Q1 2024

May 15, 2024

BUY
$18.65 - $26.52 $96,849 - $137,718
5,193 Added 18.11%
33,867 $749,000
Q4 2023

Feb 14, 2024

BUY
$16.53 - $21.42 $473,981 - $614,197
28,674 New
28,674 $608,000
Q2 2023

Aug 14, 2023

BUY
$24.77 - $29.9 $21,871 - $26,401
883 Added 2.92%
31,102 $776,000
Q1 2023

May 15, 2023

BUY
$25.95 - $36.95 $8,070 - $11,491
311 Added 1.04%
30,219 $843,000
Q4 2022

Feb 14, 2023

BUY
$24.79 - $30.86 $741,419 - $922,960
29,908 New
29,908 $779,000
Q2 2022

Aug 15, 2022

SELL
$19.74 - $29.01 $418,270 - $614,692
-21,189 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$26.68 - $41.63 $565,322 - $882,098
21,189 New
21,189 $565,000
Q3 2021

Nov 15, 2021

SELL
$30.65 - $35.68 $783,168 - $911,695
-25,552 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$34.33 - $44.68 $877,200 - $1.14 Million
25,552 New
25,552 $881,000
Q2 2018

Aug 14, 2018

SELL
$28.41 - $42.41 $511,720 - $763,888
-18,012 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$21.18 - $33.78 $381,494 - $608,445
18,012 New
18,012 $540,000

Others Institutions Holding XNCR

About Xencor Inc


  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.02B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.